3 results
The primary objective of this study is to assess the overall effectiveness of LCM (optimizedwithin the range of 200mg/day to 600mg/day) when added to a stable dose of LEV (in thelabel range of 1000mg/day to 3000mg/day) with withdrawal of the…
Primary Objective is to test the feasibility of a strategy in which patient preference, after a short exposure to treatment options, determines the choice for a specific phosphate binder and whether this strategy will improve patient*s satisfaction.…
Primary Objective:- Determine the effect of 24 weeks of oral magnesium supplementation and/or the phosphate binder sucroferric oxyhydroxide on arterial wall stiffness in CKD patients, as measured by pulse wave velocity.Secondary Objectives:-…